Talidomida (Galician Wikipedia)

Analysis of information sources in references of the Wikipedia article "Talidomida" in Galician language version.

refsWebsite

Global rank Galician rank

43nih.gov

4^th place

6^th place

37doi.org

2^nd place

7^th place

19web.archive.org

1^st place

7bbc.co.uk

8^th place

31^st place

5archive.org

6^th place

8^th place

4medscape.com

719^th place

690^th place

3nytimes.com

7^th place

32^nd place

3myelomabeacon.com

low place

2archive.today

14^th place

30^th place

2oncozine.com

low place

2harvard.edu

18^th place

38^th place

2fda.gov

447^th place

749^th place

2elmundo.es

184^th place

19^th place

2oxfordjournals.org

1,389^th place

239^th place

1oed.com

360^th place

938^th place

1answers.com

1,580^th place

993^rd place

1drugs.com

399^th place

1,875^th place

1saude.df.gov.br

low place

1who.int

195^th place

178^th place

1vectorblog.org

low place

1cancer.gov

1,684^th place

1,367^th place

1medicines.org.uk

3,823^rd place

low place

1tga.gov.au

3,984^th place

low place

1ashpublications.org

low place

1worldcat.org

5^th place

11^th place

1mhra.gov.uk

low place

1cbc.ca

115^th place

408^th place

1jstor.org

26^th place

72^nd place

1clinicaltrials.gov

5,225^th place

7,257^th place

1europa.eu

68^th place

75^th place

1ajtmh.org

low place

7,853^rd place

1bhj.org

low place

1vfa.de

low place

1avite.org

low place

1thesundaytimes.co.uk

3,908^th place

2,080^th place

1elpais.com

84^th place

10^th place

1birthdefects.org

low place

1gpo.gov

1,360^th place

1,823^rd place

1history.ca

low place

1whonamedit.com

2,888^th place

688^th place

1unsw.edu.au

4,584^th place

3,596^th place

1neues-deutschland.de

8,167^th place

low place

1aerzteblatt.de

3,043^rd place

low place

1orf.at

418^th place

3,881^st place

1imdb.com

16^th place

41^st place

1spiritualityandpractice.com

low place

1timesonline.co.uk

241^st place

395^th place

1grunenthal.info

low place

1boe.es

427^th place

29^th place

1estusanidad.com

low place

1laopinioncoruna.es

low place

27^th place

1elconfidencial.com

891^st place

142^nd place

1nihr.ac.uk

low place

aerzteblatt.de

Thomann, Klaus-Dieter (2007). "Die Contergan-Katastrophe: Die trügerische Sicherheit der "harten" Daten" [The thalidomide disaster: The false security of 'hard' data]. Deutsches Ärzteblatt (en alemán) 104 (41): A–2778 / B–2454 / C–2382. Arquivado dende o orixinal o 13 de xullo de 2015. Consultado o 6 de xuño de 2013.

ajtmh.org

Villahermosa LG, Fajardo TT, Abalos RM, Balagon MV, Tan EV, Cellona RV, Palmer JP, Wittes J, Thomas SD, Kook KA, Walsh GP, Walsh DS (Maio de 2005). "A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum" (PDF). The American Journal of Tropical Medicine and Hygiene 72 (5): 518–526. PMID 15891124. Arquivado dende o orixinal (PDF) o 04 de setembro de 2015. Consultado o 28 de xuño de 2015.

answers.com

Cuthbert, Alan (2001, 2003). The Oxford Companion to the Body. Oxford University Press. Consultado o 26 de febreiro de 2012.

archive.org

Heaton, C. A. (1994). The Chemical Industry. Springer. p. 40. ISBN 0-7514-0018-1.
Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, Dammacco F (xullo de 1994). "Bone marrow angiogenesis and progression in multiple myeloma". Br. J. Haematol. 87 (3): 503–8. PMID 7527645. doi:10.1111/j.1365-2141.1994.tb08304.x.
D'Amato RJ, Lentzsch S, Anderson KC, Rogers MS (2001). "Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma". Seminars in Oncology 28 (6): 597–601. PMID 11740816. doi:10.1016/S0093-7754(01)90031-4.
Ver Rouquette (1957) citado por Landesman-Dwyer S (1982). "Maternal drinking and pregnancy outcome". Appl Res Ment Retard 3 (3): 241–63. PMID 7149705. doi:10.1016/0270-3092(82)90018-2.
Kelsey FO (1967). "Events after thalidomide". J. Dent. Res. 46 (6): 1201–5. PMID 5235007. doi:10.1177/00220345670460061201.

archive.today

"Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the "War" Against Cancer - Onco'Zine - The International Cancer Network (3o de novembro de 30, 2013)". Arquivado dende o orixinal o 03 de xaneiro de 2014. Consultado o 28 de xuño de 2015.
"Thalidomide's Secret Past: The Link with Nazi Germany -Onco'Zine - The International Oncology Network (30 de novembro de 2013)". Arquivado dende o orixinal o 03 de xaneiro de 2014. Consultado o 28 de xuño de 2015.

ashpublications.org

Usmani, Saad Z.; Sexton, Rachel; Hoering, Antje; Heuck, Christoph J.; Nair, Bijay; Waheed, Sarah; Al Sayed, Yazan; Chauhan, Nabeel; Ahmad, Nisar (2012-08-23). "Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance". Blood (en inglés) 120 (8): 1597–1600. ISSN 0006-4971. PMC 3429303. PMID 22674807. doi:10.1182/blood-2012-04-421883.

avite.org

AVITE. Asociación de Víctimas de la Talidomida en España y otras Incapacidades AVITE

bbc.co.uk

news.bbc.co.uk

"Apology for thalidomide survivors". BBCNews:Health (BBC News). 14 de xaneiro de 2010. Consultado o 14/1/2010.
Anon (7/6/2002). "Thalidomide:40 years on". BBC news (BBC). Consultado o 2009-05-01.
Ryan, Caroline (1 de abril de 2004). "They just didn't know what it would do". BBC News:Health (BBC news). Consultado o 2009-05-01.
"Compensation offer on Thalidomide". BBC News. 7 de xullo de 2005. Consultado o 26 de xullo de 2011.
"Thalidomide survivors to get £20m". BBC News. 23 de decembro de 2009. Consultado o 26 de xullo de 2011.

bbc.co.uk

Crawford, Angus (23 de xullo de 2013). "Brazil's new generation of Thalidomide babies". BBC News.
"Thalidomide apology insulting, campaigners say". BBC News. 1 de setembro de 2012.

bhj.org

Moghe VV, Kulkarni U, Parmar UI (2008). "Thalidomide" (PDF). Bombay Hospital Journal (Bombay: Bombay Hospital) 50 (3): 473. Arquivado dende o orixinal (PDF) o 22 de xullo de 2011. Consultado o 28 de xuño de 2015.

birthdefects.org

Mekdeci, Betty. "Bendectin Part 1 (PDF link) How a Commonly Used Drug Caused Birth Defects". Arquivado dende o orixinal o 18 de decembro de 2013. Consultado o 28 de xuño de 2015.

boe.es

BOE númeo 190 do 6 de agosto de 2010. Real Decreto 1006/2010, de 5 de agosto, por el que se regula el procedimiento de concesión de ayudas a las personas afectadas por la talidomida en España durante el período 1960-1965. [3]

cancer.gov

"FDA Approval for Thalidomide". National Cancer Institute. Arquivado dende o orixinal o 28 de xaneiro de 2012. Consultado o 8 de xaneiro de 2012.

cbc.ca

"Thalidomide drug label to warn of cancer risk". CBC News. 22 de maio de 2013.

clinicaltrials.gov

"Search of: pomalidomide". Clinicaltrials.gov. Consultado o 2012-09-01.

doi.org

dx.doi.org

Srinivasan R, Akobeng AK (Apr 15, 2009). "Thalidomide and thalidomide analogues for induction of remission in Crohn's disease.". The Cochrane database of systematic reviews (2): CD007350. PMID 19370684. doi:10.1002/14651858.CD007350.pub2.
Akobeng AK, Stokkers PC (Apr 15, 2009). "Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease.". The Cochrane database of systematic reviews (2): CD007351. PMID 19370685. doi:10.1002/14651858.CD007351.pub2.
Silverman WA (agosto de 2002). "The schizophrenic career of a 'monster drug'". Pediatrics 110 (2 Pt 1): 404–6. PMID 12165600. doi:10.1542/peds.110.2.404.
Paumgartten FJ, Chahoud I (xullo de 2006). "Thalidomide embryopathy cases in Brazil after 1965". Reprod. Toxicol. 22 (1): 1–2. PMID 16427249. doi:10.1016/j.reprotox.2005.11.007.
Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (novembro de 1999). "Antitumor activity of thalidomide in refractory multiple myeloma". N. Engl. J. Med. 341 (21): 1565–71. PMID 10564685. doi:10.1056/NEJM199911183412102.
Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J (marzo de 1994). "Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers". J. Natl. Cancer Inst. 86 (5): 356–61. PMID 7508518. doi:10.1093/jnci/86.5.356.
Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, Dammacco F (xullo de 1994). "Bone marrow angiogenesis and progression in multiple myeloma". Br. J. Haematol. 87 (3): 503–8. PMID 7527645. doi:10.1111/j.1365-2141.1994.tb08304.x.
Gieseler F (xuño de 2008). "Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates". Thromb. Haemost. 99 (6): 1001–7. PMID 18521500. doi:10.1160/TH08-01-0009.
Denz U, Haas PS, Wäsch R, Einsele H, Engelhardt M (xullo de 2006). "State of the art therapy in multiple myeloma and future perspectives". Eur. J. Cancer 42 (11): 1591–600. PMID 16815703. doi:10.1016/j.ejca.2005.11.040.
Haas PS, Denz U, Ihorst G, Engelhardt M (abril de 2008). "Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses". Eur. J. Haematol. 80 (4): 303–9. PMID 18182082. doi:10.1111/j.1600-0609.2007.01022.x.
Bennett CL, Angelotta C, Yarnold PR, Evens AM, Zonder JA, Raisch DW, Richardson P (decembro de 2006). "Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer". JAMA 296 (21): 2558–60. PMID 17148721. doi:10.1001/jama.296.21.2558-c.
Usmani, Saad Z.; Sexton, Rachel; Hoering, Antje; Heuck, Christoph J.; Nair, Bijay; Waheed, Sarah; Al Sayed, Yazan; Chauhan, Nabeel; Ahmad, Nisar (2012-08-23). "Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance". Blood (en inglés) 120 (8): 1597–1600. ISSN 0006-4971. PMC 3429303. PMID 22674807. doi:10.1182/blood-2012-04-421883.
Franks ME, Macpherson GR, Figg WD (maio de 2004). "Thalidomide". Lancet 363 (9423): 1802–11. PMID 15172781. doi:10.1016/S0140-6736(04)16308-3.
Kim JH, Scialli AR (xullo de 2011). "Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease" (PDF). Toxicological Sciences 122 (1): 1–6. PMID 21507989. doi:10.1093/toxsci/kfr088.
Singhal S, Mehta J (Febreiro de 2002). "Thalidomide in cancer". Biomedicine & Pharmacotherapy 56 (1): 4–12. PMID 11905508. doi:10.1016/S0753-3322(01)00146-9.
Sarno EN, Grau GE, Vieira LM, Nery JA (abril de 1991). "Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states". Clin. Exp. Immunol. 84 (1): 103–8. PMC 1535359. PMID 2015700. doi:10.1111/j.1365-2249.1991.tb08131.x.
Stephens TD, Bunde CJ, Fillmore BJ (xuño de 2000). "Mechanism of action in thalidomide teratogenesis". Biochem. Pharmacol. 59 (12): 1489–99. PMID 10799645. doi:10.1016/S0006-2952(99)00388-3.
D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994). "Thalidomide is an inhibitor of angiogenesis". Proceedings of the National Academy of Sciences of the United States of America 91 (9): 4082–4085. Bibcode:1994PNAS...91.4082D. PMC 43727. PMID 7513432. doi:10.1073/pnas.91.9.4082.
Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N (maio de 2009). "Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation". Proc. Natl. Acad. Sci. U.S.A. 106 (21): 8573–8. Bibcode:2009PNAS..106.8573T. JSTOR 40482723. PMC 2688998. PMID 19433787. doi:10.1073/pnas.0901505106.
Teo SK, Colburn WA, Tracewell WG, Kook KA, Stirling DI, Jaworsky MS, Scheffler MA, Thomas SD, Laskin OL (2004). "Clinical pharmacokinetics of thalidomide". Clin Pharmacokinet 43 (5): 311–27. PMID 15080764. doi:10.2165/00003088-200443050-00004.
Eriksson T, Björkman S, Roth B, Fyge A, Höglund P (1995). "Stereospecific determination, chiral inversion in vitro and in humans of the enantiomers of thalidomide". Chirality 7 (1): 44–52. PMID 7702998. doi:10.1002/chir.530070109.
Muller GW, Corral LG, Shire MG, Wang H, Moreira A, Kaplan G, Stirling DI (agosto de 1996). "Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity". J. Med. Chem. 39 (17): 3238–40. PMID 8765505. doi:10.1021/jm9603328.
Man HW, Corral LG, Stirling DI, Muller GW (outubro de 2003). "Alpha-fluoro-substituted thalidomide analogues". Bioorg. Med. Chem. Lett. 13 (20): 3415–7. PMID 14505639. doi:10.1016/S0960-894X(03)00778-9.
Bartlett JB, Dredge K, Dalgleish AG (abril de 2004). "The evolution of thalidomide and its IMiD derivatives as anticancer agents". Nat. Rev. Cancer 4 (4): 314–22. PMID 15057291. doi:10.1038/nrc1323.
Man HW, Schafer P, Wong LM, Patterson RT, Corral LG, Raymon H, Blease K, Leisten J, Shirley MA, Tang Y, Babusis DM, Chen R, Stirling D, Muller GW (marzo de 2009). "Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor". J. Med. Chem. 52 (6): 1522–4. PMID 19256507. doi:10.1021/jm900210d.
Mahony C, Erskine L, Niven J, Greig NH, Figg WD, Vargesson N (2013). "Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro". Proc. Natl. Acad. Sci. U.S.A. 110 (31): 12703–8. PMC 3732931. PMID 23858438. doi:10.1073/pnas.1307684110.
Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, Mahmoudi A, Cathers B, Rychak E, Gaidarova S, Chen R, Schafer PH, Handa H, Daniel TO, Evans JF, Chopra R (2012). "Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide". Leukemia 26 (11): 2326–35. PMC 3496085. PMID 22552008. doi:10.1038/leu.2012.119.
Shah JH, Swartz GM, Papathanassiu AE, Treston AM, Fogler WE, Madsen JW, Green SJ (1999). "Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: potent inhibitors of tumor metastasis". J. Med. Chem. 42 (16): 3014–7. PMID 10447943. doi:10.1021/jm990083y.
D'Amato RJ, Lentzsch S, Anderson KC, Rogers MS (2001). "Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma". Seminars in Oncology 28 (6): 597–601. PMID 11740816. doi:10.1016/S0093-7754(01)90031-4.
Rao KV (setembro de 2007). "Lenalidomide in the treatment of multiple myeloma". Am J Health Syst Pharm 64 (17): 1799–807. PMID 17724360. doi:10.2146/ajhp070029.
Raghupathy R, Billett HH (marzo de 2009). "Promising therapies in sickle cell disease". Cardiovasc Hematol Disord Drug Targets 9 (1): 1–8. PMID 19275572. doi:10.2174/187152909787581354.
Franks ME, Macpherson GR, Figg WD (maio de 2004). "Thalidomide". Lancet 363 (9423): 1802–1811. PMID 15172781. doi:10.1016/S0140-6736(04)16308-3.
Ver Rouquette (1957) citado por Landesman-Dwyer S (1982). "Maternal drinking and pregnancy outcome". Appl Res Ment Retard 3 (3): 241–63. PMID 7149705. doi:10.1016/0270-3092(82)90018-2.
Kelsey FO (1967). "Events after thalidomide". J. Dent. Res. 46 (6): 1201–5. PMID 5235007. doi:10.1177/00220345670460061201.
Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM (abril de 2005). "Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial" (PDF). GUT 54 (4): 540–545. PMC 1774430. PMID 15753541. doi:10.1136/gut.2004.047563.
Sharpstone D, Rowbottom A, Francis N, Tovey G, Ellis D, Barrett M, Gazzard B (xuño de 1997). "Thalidomide: a novel therapy for microsporidiosis". Gastroenterology 112 (6): 1823–1829. PMID 9178672. doi:10.1053/gast.1997.v112.pm9178672.
Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, Zwingenberger K, Yazici H (marzo de 1998). "Thalidomide in the treatment of the mucocutaneous lesions of the Behcet Syndrome: a randomized, double-blind, placebo-controlled trial". Annals of Internal Medicine 128 (6): 443–450. PMID 9499327. doi:10.7326/0003-4819-128-6-199803150-00004.

drugs.com

"Thalidomide". The American Society of Health-System Pharmacists. Consultado o xuño de 2014.

elconfidencial.com

El Confidencial. Eurodiputados piden a Alemania que reciba a afectados de talidomida. [6]

elmundo.es

El Mundo. Las víctimas de la talidomida, contentas con la sentencia
El Mundo. La Audiencia Provincial de Madrid anula la indemnización a los afectados por la talidomida. [4]

elpais.com

politica.elpais.com

El País. La Audiencia anula la indemnización a los afectados por la talidomida [2]

estusanidad.com

"estusanidad. El "desempate" de la talidomida ya tiene fecha". Arquivado dende o orixinal o 04 de xullo de 2015. Consultado o 03 de xullo de 2015.

europa.eu

ema.europa.eu

"Thalidomide Celgene : EPAR - Product Information" (PDF). European Medicines Agency. Celgene Europe Limited. 29 de agosto de 2013. Arquivado dende o orixinal (PDF) o 03 de xullo de 2015. Consultado o 19 de xaneiro de 2014.

fda.gov

Informe na páxina web de FDA norteamericana.
"50 Years: The Kefauver-Harris Amendments". Food and Drug Administration (United States). Consultado o 6 de xuño de 2013.

gpo.gov

permanent.access.gpo.gov

Bren L (2001-02-28). "Frances Oldham Kelsey: FDA Medical Reviewer Leaves Her Mark on History". FDA Consumer (U.S. Food and Drug Administration). Consultado o 2009-12-23.

grunenthal.info

contergan.grunenthal.info

"Speech on the occasion of the inauguration of Thalidomide-Memorial; Grünenthal GmbH Website (consultado o 3 de decembro de 2013)". Arquivado dende o orixinal o 01 de setembro de 2012. Consultado o 28 de xuño de 2015.

harvard.edu

adsabs.harvard.edu

D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994). "Thalidomide is an inhibitor of angiogenesis". Proceedings of the National Academy of Sciences of the United States of America 91 (9): 4082–4085. Bibcode:1994PNAS...91.4082D. PMC 43727. PMID 7513432. doi:10.1073/pnas.91.9.4082.
Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N (maio de 2009). "Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation". Proc. Natl. Acad. Sci. U.S.A. 106 (21): 8573–8. Bibcode:2009PNAS..106.8573T. JSTOR 40482723. PMC 2688998. PMID 19433787. doi:10.1073/pnas.0901505106.

history.ca

"Turning Points of History–Prescription for Disaster". History Television. Arquivado dende o orixinal o 29 de setembro de 2011. Consultado o 24 de febreiro de 2010.

imdb.com

"NoBody's Perfect (2008): Release Info". IMDB. Consultado o 6 de xuño de 2013.

jstor.org

Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N (maio de 2009). "Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation". Proc. Natl. Acad. Sci. U.S.A. 106 (21): 8573–8. Bibcode:2009PNAS..106.8573T. JSTOR 40482723. PMC 2688998. PMID 19433787. doi:10.1073/pnas.0901505106.

laopinioncoruna.es

La Opinión. A Coruña. El Parlamento Europeo apoya a las víctimas españolas de la talidomida. [5]

medicines.org.uk

"Thalidomide Celgene 50 mg Hard Capsules". electronic Medicines Compendium. Celgene Ltd. 1 de agosto de 2013. Consultado o 17 de xaneiro de 2014.

medscape.com

Lewis, R (26 novembro de 2013). "Thalidomide Induced Remission in Early-Onset Crohn's Disease". Medscape Medical News. WebMD. Consultado o 19 de xaneiro de 2014.
Okafor, MC (2003). "Thalidomide for Erythema Nodosum Leprosum and Other Applications". Medscape Medical News. WebMD. Consultado o 19 de xaneiro de 2014.

reference.medscape.com

"Thalomid (thalidomide) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Consultado o 17 de xaneiro de 2014.

emedicine.medscape.com

Rose, LJ; Fishman, AD; Sparano, JA (11 de marzo de 2013). Talavera, F; McKenna, R; Harris, JE, ed. "Kaposi Sarcoma Treatment & Management". Medscape Reference. WebMD. Consultado o 19 de xaneiro de 2014.

mhra.gov.uk

"Thalidomide: risk of second primary malignancies". Medicines and Healthcare products Regulatory Agency. maio de 2013. Consultado o 17 de xaneiro de 2014.

myelomabeacon.com

The Myeloma Beacon Staff (8 de abril de 2011). "FDA Announces Investigation Into Revlimid, Thalidomide, And Secondary Cancers". The Myeloma Beacon. Consultado o 17 de xaneiro de 2014.
"Pomalyst (Pomalidomide) Approved By FDA For Relapsed And Refractory Multiple Myeloma". The Myeloma Beacon. Arquivado dende o orixinal o 07 de xaneiro de 2014. Consultado o 2013-08-10.
"Pomalidomide Approved In Europe For Relapsed And Refractory Multiple Myeloma". The Myeloma Beacon. Arquivado dende o orixinal o 18/01/2014. Consultado o 10/8/2013.

neues-deutschland.de

"DDR-Bürger schliefen ohne Contergan" [East German citizens slept without thalidomide]. Neues Deutschland (en alemán). 4 de novembro de 2007. Consultado o 6 de xuño de 2013.

nih.gov

ncbi.nlm.nih.gov

Srinivasan R, Akobeng AK (Apr 15, 2009). "Thalidomide and thalidomide analogues for induction of remission in Crohn's disease.". The Cochrane database of systematic reviews (2): CD007350. PMID 19370684. doi:10.1002/14651858.CD007350.pub2.
Akobeng AK, Stokkers PC (Apr 15, 2009). "Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease.". The Cochrane database of systematic reviews (2): CD007351. PMID 19370685. doi:10.1002/14651858.CD007351.pub2.
Silverman WA (agosto de 2002). "The schizophrenic career of a 'monster drug'". Pediatrics 110 (2 Pt 1): 404–6. PMID 12165600. doi:10.1542/peds.110.2.404.
Castilla EE, Ashton-Prolla P, Barreda-Mejia E, Brunoni D, Cavalcanti DP, Correa-Neto J, Delgadillo JL, Dutra MG, Felix T, Giraldo A, Juarez N, Lopez-Camelo JS, Nazer J, Orioli IM, Paz JE, Pessoto MA, Pina-Neto JM, Quadrelli R, Rittler M, Rueda S, Saltos M, Sánchez O, Schüler L (decembro de 1996). "Thalidomide, a current teratogen in South America". Teratology 54 (6): 273–7. PMID 9098920. doi:10.1002/(SICI)1096-9926(199612)54:6<273::AID-TERA1>3.0.CO;2-# (inactivo 2015-01-09).
Paumgartten FJ, Chahoud I (xullo de 2006). "Thalidomide embryopathy cases in Brazil after 1965". Reprod. Toxicol. 22 (1): 1–2. PMID 16427249. doi:10.1016/j.reprotox.2005.11.007.
Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (novembro de 1999). "Antitumor activity of thalidomide in refractory multiple myeloma". N. Engl. J. Med. 341 (21): 1565–71. PMID 10564685. doi:10.1056/NEJM199911183412102.
Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J (marzo de 1994). "Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers". J. Natl. Cancer Inst. 86 (5): 356–61. PMID 7508518. doi:10.1093/jnci/86.5.356.
Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, Dammacco F (xullo de 1994). "Bone marrow angiogenesis and progression in multiple myeloma". Br. J. Haematol. 87 (3): 503–8. PMID 7527645. doi:10.1111/j.1365-2141.1994.tb08304.x.
Gieseler F (xuño de 2008). "Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates". Thromb. Haemost. 99 (6): 1001–7. PMID 18521500. doi:10.1160/TH08-01-0009.
Denz U, Haas PS, Wäsch R, Einsele H, Engelhardt M (xullo de 2006). "State of the art therapy in multiple myeloma and future perspectives". Eur. J. Cancer 42 (11): 1591–600. PMID 16815703. doi:10.1016/j.ejca.2005.11.040.
Haas PS, Denz U, Ihorst G, Engelhardt M (abril de 2008). "Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses". Eur. J. Haematol. 80 (4): 303–9. PMID 18182082. doi:10.1111/j.1600-0609.2007.01022.x.
Bennett CL, Angelotta C, Yarnold PR, Evens AM, Zonder JA, Raisch DW, Richardson P (decembro de 2006). "Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer". JAMA 296 (21): 2558–60. PMID 17148721. doi:10.1001/jama.296.21.2558-c.
Usmani, Saad Z.; Sexton, Rachel; Hoering, Antje; Heuck, Christoph J.; Nair, Bijay; Waheed, Sarah; Al Sayed, Yazan; Chauhan, Nabeel; Ahmad, Nisar (2012-08-23). "Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance". Blood (en inglés) 120 (8): 1597–1600. ISSN 0006-4971. PMC 3429303. PMID 22674807. doi:10.1182/blood-2012-04-421883.
Franks ME, Macpherson GR, Figg WD (maio de 2004). "Thalidomide". Lancet 363 (9423): 1802–11. PMID 15172781. doi:10.1016/S0140-6736(04)16308-3.
Webb JF (novembro de 1963). "Canadian Thalidomide Experience". Can Med Assoc J 89: 987–92. PMC 1921912. PMID 14076167.
Kim JH, Scialli AR (xullo de 2011). "Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease" (PDF). Toxicological Sciences 122 (1): 1–6. PMID 21507989. doi:10.1093/toxsci/kfr088.
Singhal S, Mehta J (Febreiro de 2002). "Thalidomide in cancer". Biomedicine & Pharmacotherapy 56 (1): 4–12. PMID 11905508. doi:10.1016/S0753-3322(01)00146-9.
Sarno EN, Grau GE, Vieira LM, Nery JA (abril de 1991). "Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states". Clin. Exp. Immunol. 84 (1): 103–8. PMC 1535359. PMID 2015700. doi:10.1111/j.1365-2249.1991.tb08131.x.
Stephens TD, Bunde CJ, Fillmore BJ (xuño de 2000). "Mechanism of action in thalidomide teratogenesis". Biochem. Pharmacol. 59 (12): 1489–99. PMID 10799645. doi:10.1016/S0006-2952(99)00388-3.
D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994). "Thalidomide is an inhibitor of angiogenesis". Proceedings of the National Academy of Sciences of the United States of America 91 (9): 4082–4085. Bibcode:1994PNAS...91.4082D. PMC 43727. PMID 7513432. doi:10.1073/pnas.91.9.4082.
Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N (maio de 2009). "Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation". Proc. Natl. Acad. Sci. U.S.A. 106 (21): 8573–8. Bibcode:2009PNAS..106.8573T. JSTOR 40482723. PMC 2688998. PMID 19433787. doi:10.1073/pnas.0901505106.
Teo SK, Colburn WA, Tracewell WG, Kook KA, Stirling DI, Jaworsky MS, Scheffler MA, Thomas SD, Laskin OL (2004). "Clinical pharmacokinetics of thalidomide". Clin Pharmacokinet 43 (5): 311–27. PMID 15080764. doi:10.2165/00003088-200443050-00004.
Eriksson T, Björkman S, Roth B, Fyge A, Höglund P (1995). "Stereospecific determination, chiral inversion in vitro and in humans of the enantiomers of thalidomide". Chirality 7 (1): 44–52. PMID 7702998. doi:10.1002/chir.530070109.
Muller GW, Corral LG, Shire MG, Wang H, Moreira A, Kaplan G, Stirling DI (agosto de 1996). "Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity". J. Med. Chem. 39 (17): 3238–40. PMID 8765505. doi:10.1021/jm9603328.
Man HW, Corral LG, Stirling DI, Muller GW (outubro de 2003). "Alpha-fluoro-substituted thalidomide analogues". Bioorg. Med. Chem. Lett. 13 (20): 3415–7. PMID 14505639. doi:10.1016/S0960-894X(03)00778-9.
Bartlett JB, Dredge K, Dalgleish AG (abril de 2004). "The evolution of thalidomide and its IMiD derivatives as anticancer agents". Nat. Rev. Cancer 4 (4): 314–22. PMID 15057291. doi:10.1038/nrc1323.
Man HW, Schafer P, Wong LM, Patterson RT, Corral LG, Raymon H, Blease K, Leisten J, Shirley MA, Tang Y, Babusis DM, Chen R, Stirling D, Muller GW (marzo de 2009). "Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor". J. Med. Chem. 52 (6): 1522–4. PMID 19256507. doi:10.1021/jm900210d.
Mahony C, Erskine L, Niven J, Greig NH, Figg WD, Vargesson N (2013). "Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro". Proc. Natl. Acad. Sci. U.S.A. 110 (31): 12703–8. PMC 3732931. PMID 23858438. doi:10.1073/pnas.1307684110.
Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, Mahmoudi A, Cathers B, Rychak E, Gaidarova S, Chen R, Schafer PH, Handa H, Daniel TO, Evans JF, Chopra R (2012). "Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide". Leukemia 26 (11): 2326–35. PMC 3496085. PMID 22552008. doi:10.1038/leu.2012.119.
Shah JH, Swartz GM, Papathanassiu AE, Treston AM, Fogler WE, Madsen JW, Green SJ (1999). "Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: potent inhibitors of tumor metastasis". J. Med. Chem. 42 (16): 3014–7. PMID 10447943. doi:10.1021/jm990083y.
D'Amato RJ, Lentzsch S, Anderson KC, Rogers MS (2001). "Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma". Seminars in Oncology 28 (6): 597–601. PMID 11740816. doi:10.1016/S0093-7754(01)90031-4.
Rao KV (setembro de 2007). "Lenalidomide in the treatment of multiple myeloma". Am J Health Syst Pharm 64 (17): 1799–807. PMID 17724360. doi:10.2146/ajhp070029.
Raghupathy R, Billett HH (marzo de 2009). "Promising therapies in sickle cell disease". Cardiovasc Hematol Disord Drug Targets 9 (1): 1–8. PMID 19275572. doi:10.2174/187152909787581354.
Franks ME, Macpherson GR, Figg WD (maio de 2004). "Thalidomide". Lancet 363 (9423): 1802–1811. PMID 15172781. doi:10.1016/S0140-6736(04)16308-3.
Waters MF (marzo de 1971). "An internally-controlled double blind trial of thalidomide in severe erythema nodosum leprosum". Leprosy Review 42 (1): 26–42. PMID 4338720.
Villahermosa LG, Fajardo TT, Abalos RM, Balagon MV, Tan EV, Cellona RV, Palmer JP, Wittes J, Thomas SD, Kook KA, Walsh GP, Walsh DS (Maio de 2005). "A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum" (PDF). The American Journal of Tropical Medicine and Hygiene 72 (5): 518–526. PMID 15891124. Arquivado dende o orixinal (PDF) o 04 de setembro de 2015. Consultado o 28 de xuño de 2015.
Ver Rouquette (1957) citado por Landesman-Dwyer S (1982). "Maternal drinking and pregnancy outcome". Appl Res Ment Retard 3 (3): 241–63. PMID 7149705. doi:10.1016/0270-3092(82)90018-2.
Kelsey FO (1967). "Events after thalidomide". J. Dent. Res. 46 (6): 1201–5. PMID 5235007. doi:10.1177/00220345670460061201.
Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM (abril de 2005). "Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial" (PDF). GUT 54 (4): 540–545. PMC 1774430. PMID 15753541. doi:10.1136/gut.2004.047563.
Sharpstone D, Rowbottom A, Francis N, Tovey G, Ellis D, Barrett M, Gazzard B (xuño de 1997). "Thalidomide: a novel therapy for microsporidiosis". Gastroenterology 112 (6): 1823–1829. PMID 9178672. doi:10.1053/gast.1997.v112.pm9178672.
Tunio MA, Hashmi A, Qayyum A, Naimatullah N, Masood R (setembro de 2012). "Low-dose thalidomide in patients with metastatic renal cell carcinoma". Journal of the Pakistan Medical Association 62 (9): 876–879. PMID 23139966.
Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, Zwingenberger K, Yazici H (marzo de 1998). "Thalidomide in the treatment of the mucocutaneous lesions of the Behcet Syndrome: a randomized, double-blind, placebo-controlled trial". Annals of Internal Medicine 128 (6): 443–450. PMID 9499327. doi:10.7326/0003-4819-128-6-199803150-00004.

dailymed.nlm.nih.gov

"THALOMID (thalidomide) capsule [Celgene Corporation]". DailyMed. Celgene Corporation. n novembro de 2013. Consultado o 17 de xaneiro de 2014.

nihr.ac.uk

crncc.nihr.ac.uk

"Thalidomide". National Health Service (England). Arquivado dende o orixinal o 03 de decembro de 2013. Consultado o 6 de xuño de 2013.

nytimes.com

Sheryl Gay Stolberg (17 de xullo de 1998). "Thalidomide Approved to Treat Leprosy, With Other Uses Seen". New York Times. Consultado o 8 de xaneiro de 2012.
Zimmer C (15 de marzo de 2010). "Answers Begin to Emerge on How Thalidomide Caused Defects". New York Times. Consultado o 2010-03-21. Como informan no número actual de Science, unha proteína coñecida como cereblon acoplada estreitamente á talidomida
"The Public's Quiet Savior From Harmful Medicines". The New York Times. 13 de setembro de 2010.

oed.com

"Thalidomide". Oxford English Dictionary (3rd ed.). Oxford University Press. Setembro de 2005. [1] Arquivado 30 de xuño de 2015 en Wayback Machine.

oncozine.com

"Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the "War" Against Cancer - Onco'Zine - The International Cancer Network (3o de novembro de 30, 2013)". Arquivado dende o orixinal o 03 de xaneiro de 2014. Consultado o 28 de xuño de 2015.
"Thalidomide's Secret Past: The Link with Nazi Germany -Onco'Zine - The International Oncology Network (30 de novembro de 2013)". Arquivado dende o orixinal o 03 de xaneiro de 2014. Consultado o 28 de xuño de 2015.

orf.at

"10.000 Fälle von Missbildungen" [10,000 cases of malformations] (en alemán). ORF. Arquivado dende o orixinal o 14 de agosto de 2009. Consultado o 6 de xuño de 2013.

oxfordjournals.org

jnci.oxfordjournals.org

Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J (marzo de 1994). "Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers". J. Natl. Cancer Inst. 86 (5): 356–61. PMID 7508518. doi:10.1093/jnci/86.5.356.

toxsci.oxfordjournals.org

Kim JH, Scialli AR (xullo de 2011). "Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease" (PDF). Toxicological Sciences 122 (1): 1–6. PMID 21507989. doi:10.1093/toxsci/kfr088.

saude.df.gov.br

Correio Braziliense (xaneiro de 2006). "Talidomida volta a assustar". Arquivado dende o orixinal o 13 de marzo de 2012. Consultado o 28 de xuño de 2015.

spiritualityandpractice.com

Brussat, Frederic; Brussat, Mary Ann. "Film Review: NoBody's Perfect". Spirituality & Practice. Consultado o 6 de xuño de 2013.

tga.gov.au

ebs.tga.gov.au

"THALOMID® CAPSULES" (PDF). TGA eBusiness Services. Celgene Pty Limited. 21 de xuño de 2013. Consultado o 17 de xaneiro de 2014.

thesundaytimes.co.uk

Scott, Caroline; Haupt, Oliver (3 de maio de 2015). "The forgotten victims". The Sunday Times Magazine. pp. 12–19. Arquivado dende o orixinal o 27 de maio de 2015. Consultado o 8 de maio de 2015.

timesonline.co.uk

Flintoff, John-Paul (23 de marzo de 2008). "Thalidomide: the battle for compensation goes on". The Sunday Times (London: Times Newspapers Ltd.). Arquivado dende o orixinal o 13 de maio de 2008. Consultado o 2009-05-01.

unsw.edu.au

embryology.med.unsw.edu.au

"Report of Thalidomide at University of New South Wales". Embryology.med.unsw.edu.au. Arquivado dende o orixinal o 28 de outubro de 2012. Consultado o 2012-12-30.

vectorblog.org

David Altman (2013-04-02). "From thalidomide to Pomalyst: Better living through chemistry — Vector". Vectorblog.org. Arquivado dende o orixinal o 07 de xaneiro de 2014. Consultado o 2013-05-22.

vfa.de

VFA: teratogenic effects 6. Xullo de 2011.

web.archive.org

"Thalidomide". Oxford English Dictionary (3rd ed.). Oxford University Press. Setembro de 2005. [1] Arquivado 30 de xuño de 2015 en Wayback Machine.
Correio Braziliense (xaneiro de 2006). "Talidomida volta a assustar". Arquivado dende o orixinal o 13 de marzo de 2012. Consultado o 28 de xuño de 2015.
David Altman (2013-04-02). "From thalidomide to Pomalyst: Better living through chemistry — Vector". Vectorblog.org. Arquivado dende o orixinal o 07 de xaneiro de 2014. Consultado o 2013-05-22.
"FDA Approval for Thalidomide". National Cancer Institute. Arquivado dende o orixinal o 28 de xaneiro de 2012. Consultado o 8 de xaneiro de 2012.
"Pomalyst (Pomalidomide) Approved By FDA For Relapsed And Refractory Multiple Myeloma". The Myeloma Beacon. Arquivado dende o orixinal o 07 de xaneiro de 2014. Consultado o 2013-08-10.
"Pomalidomide Approved In Europe For Relapsed And Refractory Multiple Myeloma". The Myeloma Beacon. Arquivado dende o orixinal o 18/01/2014. Consultado o 10/8/2013.
"Thalidomide Celgene : EPAR - Product Information" (PDF). European Medicines Agency. Celgene Europe Limited. 29 de agosto de 2013. Arquivado dende o orixinal (PDF) o 03 de xullo de 2015. Consultado o 19 de xaneiro de 2014.
Villahermosa LG, Fajardo TT, Abalos RM, Balagon MV, Tan EV, Cellona RV, Palmer JP, Wittes J, Thomas SD, Kook KA, Walsh GP, Walsh DS (Maio de 2005). "A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum" (PDF). The American Journal of Tropical Medicine and Hygiene 72 (5): 518–526. PMID 15891124. Arquivado dende o orixinal (PDF) o 04 de setembro de 2015. Consultado o 28 de xuño de 2015.
Moghe VV, Kulkarni U, Parmar UI (2008). "Thalidomide" (PDF). Bombay Hospital Journal (Bombay: Bombay Hospital) 50 (3): 473. Arquivado dende o orixinal (PDF) o 22 de xullo de 2011. Consultado o 28 de xuño de 2015.
Scott, Caroline; Haupt, Oliver (3 de maio de 2015). "The forgotten victims". The Sunday Times Magazine. pp. 12–19. Arquivado dende o orixinal o 27 de maio de 2015. Consultado o 8 de maio de 2015.
Mekdeci, Betty. "Bendectin Part 1 (PDF link) How a Commonly Used Drug Caused Birth Defects". Arquivado dende o orixinal o 18 de decembro de 2013. Consultado o 28 de xuño de 2015.
"Turning Points of History–Prescription for Disaster". History Television. Arquivado dende o orixinal o 29 de setembro de 2011. Consultado o 24 de febreiro de 2010.
"Report of Thalidomide at University of New South Wales". Embryology.med.unsw.edu.au. Arquivado dende o orixinal o 28 de outubro de 2012. Consultado o 2012-12-30.
Thomann, Klaus-Dieter (2007). "Die Contergan-Katastrophe: Die trügerische Sicherheit der "harten" Daten" [The thalidomide disaster: The false security of 'hard' data]. Deutsches Ärzteblatt (en alemán) 104 (41): A–2778 / B–2454 / C–2382. Arquivado dende o orixinal o 13 de xullo de 2015. Consultado o 6 de xuño de 2013.
"10.000 Fälle von Missbildungen" [10,000 cases of malformations] (en alemán). ORF. Arquivado dende o orixinal o 14 de agosto de 2009. Consultado o 6 de xuño de 2013.
Flintoff, John-Paul (23 de marzo de 2008). "Thalidomide: the battle for compensation goes on". The Sunday Times (London: Times Newspapers Ltd.). Arquivado dende o orixinal o 13 de maio de 2008. Consultado o 2009-05-01.
"Speech on the occasion of the inauguration of Thalidomide-Memorial; Grünenthal GmbH Website (consultado o 3 de decembro de 2013)". Arquivado dende o orixinal o 01 de setembro de 2012. Consultado o 28 de xuño de 2015.
"estusanidad. El "desempate" de la talidomida ya tiene fecha". Arquivado dende o orixinal o 04 de xullo de 2015. Consultado o 03 de xullo de 2015.
"Thalidomide". National Health Service (England). Arquivado dende o orixinal o 03 de decembro de 2013. Consultado o 6 de xuño de 2013.

who.int

Anon. "Use of thalidomide in leprosy". WHO:leprosy elimination. WHO. Consultado o 22 de abril de 2010.

whonamedit.com

Anon. "Widukind Lenz". who name it?. Ole Daniel Enersen. Consultado o 1/5/2009.

worldcat.org

Usmani, Saad Z.; Sexton, Rachel; Hoering, Antje; Heuck, Christoph J.; Nair, Bijay; Waheed, Sarah; Al Sayed, Yazan; Chauhan, Nabeel; Ahmad, Nisar (2012-08-23). "Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance". Blood (en inglés) 120 (8): 1597–1600. ISSN 0006-4971. PMC 3429303. PMID 22674807. doi:10.1182/blood-2012-04-421883.